CD47 and neoplasm: Although repeated administration of 4N1K has been shown to reduce tumour growth and Ki‐67 expression in preclinical models, subsequent research indicated that these effects might be due to nonspecific protein binding rather than specific CD47 engagement, necessitating cautious interpretation of results.